NGF and Alzheimer disease: NGF delivery via CERE-110, an adeno-associated virus-based gene delivery vector encoding for human NGF, showed sustained NGF expression in rodents for 12 months [17], and it was found to be safe and well-tolerated in patients with AD in a 2-year pilot study [18].